Cannabinoid Type 2 Receptor Activation Reduces the Progression of Kidney Fibrosis Using a Mouse Model of Unilateral Ureteral Obstruction.

Swanson, Mallory L; Regner, Kevin R; Moore, Bob M; Park, Frank

Swanson, Mallory L; Regner, Kevin R; Moore, Bob M; Park, Frank.

Afiliación

Swanson ML; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Regner KR; Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Moore BM; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Park F; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

Cannabis Cannabinoid Res ; 7(6): 790-803, 2022 12.

Article en En | MEDLINE | ID: mdl-35196117

Asunto(s)

Cannabinoides; Obstrucción Ureteral; Humanos; Obstrucción Ureteral/tratamiento farmacológico; Receptores de Cannabinoides; Cannabinoides/farmacología; Fibrosis; Riñón

Palabras clave

CB2 receptor agonist; SMM-295; kidney fibrosis; unilateral ureteral obstruction

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Obstrucción Ureteral / Cannabinoides Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Cannabis Cannabinoid Res Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google